Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 5/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494696 | 1.00 | RELA (0.68) | RELATRPA1NFE2L2APPCYP19A1 | |
| SCHEMBL5494942 | 0.91 | RELA (0.82) | RELATRPA1NFE2L2APPCYP19A1 | |
| SCHEMBL5494946 | 0.91 | RELA (0.82) | RELATRPA1NFE2L2APPCYP19A1 | |
| SCHEMBL10015726 | 0.90 | RELA (0.69) | RELANFE2L2APPCYP19A1CYP1A1 | |
| SCHEMBL16167740 | 0.90 | RELA (0.69) | RELANFE2L2APPCYP19A1CYP1A1 | |
| SCHEMBL16311931 | 0.90 | RELA (0.69) | RELANFE2L2APPCYP19A1CYP1A1 | |
| SCHEMBL5491678 | 0.89 | RELA (0.58) | RELATRPA1NFE2L2CYP19A1CYP1A1 | |
| SCHEMBL5491677 | 0.89 | RELA (0.58) | RELATRPA1NFE2L2CYP19A1CYP1A1 | |
| SCHEMBL8943695 | 0.88 | RELA (0.56) | RELATRPA1NFE2L2CYP19A1CYP1A1 | |
| SCHEMBL8943692 | 0.88 | RELA (0.56) | RELATRPA1NFE2L2CYP19A1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276627-B2 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060224017-A1 | One pot sequential reactions and novel products produced thereby | PNMT, CYP1A1, TERT | RELA 1503/4885TRPA1 1677/4885NFE2L2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.